



# The importance of microRNA-23a in diagnosis neonatal sepsis

**Ahlam Fatmi<sup>1</sup>, Wiam Saadi<sup>2</sup>, Yamina Elhabiri<sup>3</sup>, José Luis García-Giménez<sup>4,5</sup>, Federico V. Pallardó<sup>4,5\*</sup>**

<sup>1</sup>Laboratory of Applied Molecular Biology and Immunology, W0414100, Tlemcen, Algeria.

<sup>2</sup>Department of Biology, Faculty of Nature, Life and Earth Sciences, University of Djillali Bounaama, Khemis Miliana  
44225, Algeria.

<sup>3</sup>Laboratory of Microbiology Applied to the Food at the Biomedical and Environmental, Tlemcen, Algeria.

<sup>4</sup>Center for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Valencia,  
Spain.

<sup>5</sup>Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain.  
[ahlem.fatmi@gmail.com](mailto:ahlem.fatmi@gmail.com)

**Background:** sepsis remains the third leading cause of morbidity and mortality in neonatal period. The ability to diagnose neonatal sepsis rapidly and reliably based on clinical assessment and laboratory blood testing remains a challenge. Furthermore, due to a scarcity of samples, research is extremely challenging. The aim of this study was to investigate the role of microRNA-23a in the diagnosis of neonatal sepsis.

## Materials and methods




Figure 1. Planning of prospective study



## The importance of microRNA-23a in diagnosis neonatal sepsis

**Ahlem Fatmi<sup>1</sup>, Wiam Saadi<sup>2</sup>, Yamina Elhabiri<sup>3</sup>, José Luis García-Giménez<sup>4,5</sup>, Federico V. Pallardó<sup>4,5\*</sup>**

<sup>1</sup>Laboratory of Applied Molecular Biology and Immunology, W04/14100, Tlemcen, Algeria.




<sup>2</sup>Department of Biology, Faculty of Nature, Life and Earth Sciences, University of Djillali Bouaama, Khemis Miliana 44225,

Algeria.  
<sup>3</sup>Laboratory of Microbiology Applied to the Food at the Biomedical and Environmental, Tlemcen, Algeria.

<sup>4</sup>Center for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Valencia, Spain.

<sup>5</sup>Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain.

[ahlem.fatmi@gmail.com](mailto:ahlem.fatmi@gmail.com)



**Figure 2:** Changes in miRNA-23a expression levels in early onset sepsis (EOS) and late onset sepsis (LOS)

**Results:** We have shown that miRNA-23a expression levels increased in full-term newborns in the case of EOS without signification ( $p < 0,904$ ), but decreased in LOS in full-term ( $p < 0,031$ ) when compared to the respective negative controls. We have also observed that these levels are different between the first days of life and other week, with the level of miRNA-23a increasing in LOS negative controls compared to EOS negative controls ( $p < 0,05$ ).

**Conclusions:** Despite the limited number of samples, these results collectively demonstrate that miR-23a is involved in the host response to neonatal sepsis. Therefore, the decrease in miRNA-23a expression levels would undoubtedly be an important factor favoring the development of sepsis and suggesting their utility as a biomarker in both molecular diagnosis and patient monitoring.